$199,999,935
PIPE
November 2024
Biopharma
Eason Hahm
Director, Biopharma
About Eason
Eason Hahm is a director for William Blair based in the firm’s Boston office. She originally joined William Blair's investment banking team in 2012 and rejoined in 2018 after completing her M.B.A.
Notable Transactions
$293,250,000
Initial Public Offering
October 2024
Biopharma
Last week, William Blair acted as an underwriter on three healthcare IPOs: Upstream Bio’s (NASDAQ:UPB) $293 million IPO, CAMP4 Therapeutics’ (NASDAQ: CAMP) $75 million IPO, and Ceribell’s (NASDAQ: CBLL) $207 million IPO.
Read more
$34,600,000
PIPE
April 2024
Biopharma
$632,540,250
Follow-on Offering
February 2024
Biopharma
$143,750,000
Follow-on Offering
November 2023
Biopharma
$181,558,492
Follow-on Offering
Lead Capital Markets Advisor
June 2023
Biopharma
$287,510,350
Follow-on Offering
March 2023
Biopharma
$40,266,204
PIPE
December 2022
Biopharma
$326,000,000
has merged with
November 2022
Biopharma
William Blair is acting as financial advisor, capital markets advisor, and PIPE placement agent to Frazier Lifesciences Acquisition Corporation (NASDAQ: FLAC) in connection with its pending merger with NewAmsterdam Pharma Holding B.V.
Read more
$234,600,000
PIPE
November 2022
Biopharma
William Blair is acting as financial advisor, capital markets advisor, and PIPE placement agent to Frazier Lifesciences Acquisition Corporation (NASDAQ: FLAC) in connection with its pending merger with NewAmsterdam Pharma Holding B.V.
Read more
$80,510,063
Follow-on Offering
September 2022
Biopharma
$258,750,018
Follow-on Offering
July 2022
Biopharma
Rigorous pursuit of your success. Every transaction. Every time.
Our investment bankers are 100 percent committed to your organization’s sustained success. By drawing on our deep industry and product experience as well as our dedicated global resources, we provide advisory and financing services that allow you to capitalize on today’s opportunities and anticipate tomorrow’s challenges.
More about investment banking at William Blair
Biopharma
The rapid and cost-effective development of innovative therapeutics and treatments is critical not just to public health, but to the functioning of society and economic activity. Leading drug developers, as well as their partners across the research, development, and manufacturing value chain, count on William Blair’s deep expertise in biopharma’s capital-raising and deal-making landscape.
More about our biopharma expertise
About William Blair
William Blair is a premier global boutique with expertise in investment banking, investment management, and private wealth management. We provide advisory services, strategies, and solutions to meet our clients’ evolving needs. As an independent and employee-owned firm, together with our strategic partners, we operate in more than 20 offices worldwide.*
-
1935Year William Blair was founded
-
1,900+Employees worldwide
-
147 billion+Client assets
-
90 YearsIndependent and employee-owned
-
20+Offices worldwide
-
~650Companies under coverage
As of December 31, 2024
*Includes strategic partnerships with Allier Capital, BDA Partners, and Poalim Capital Markets.